NCT04368429View on ClinicalTrials.gov

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

May 22, 2020

Primary Completion Date

November 7, 2020

Study Completion Date

November 7, 2020

Conditions
Meningococcal Immunisation (Healthy Volunteers)
Interventions
BIOLOGICAL

Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)

Pharmaceutical form: Liquid solution Route of administration: IM

BIOLOGICAL

Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

Pharmaceutical form: Liquid solution Route of administration: IM

Trial Locations (4)

Unknown

Investigational Site Number 3920001, Koganeishi

Investigational Site Number 3920004, Nagoya

Investigational Site Number 3920002, Shinjuku-Ku

Investigational Site Number 3920003, Shinjuku-Ku

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT04368429 - Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age | Biotech Hunter | Biotech Hunter